Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) has completed the capital increase in the full amount of one million new shares very successfully. The subscription and placement price was set at CHF 122.50 after the expiry of the subscription and placement period, which ended on 23 June 2022 at 12:00 CEST. The issue price corresponds to the volume-weighted average price from 21 to 23 June 2022, until 12:00 noon, with a discount of 2.1%. The capital increase with a transaction volume of CHF 122.5 million met with great interest and was significantly oversubscribed. The new shares are eligible for the dividend payment of 06 July 2022. Zürcher Kantonalbank is the Sole Global Coordinator of this capital increase.

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – The Board of Directors of Ypsomed (SIX: YPSN) decided in its meeting on Monday, 13 June 2022, to carry out a capital increase from authorised capital created by the resolution of the Annual General Meeting on Wednesday, 30 June 2021, in the amount of a maximum of 1 million fully paid registered shares with a nominal value of CHF 14.15 each. The new shares will be offered to the existing shareholders at market conditions with a discount expected to be between 2% to 3%, while maintaining the subscription rights. It is envisaged to sell the unsubscribed shares in a free placement. There will be no trading of subscription rights. The new shares will be eligible for the dividend payment of 06 July 2022. Zürcher Kantonalbank is the Sole Global Coordinator of this capital increase.

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) generated a growth in sales of 15.2% in the financial year 2021/22 compared to the previous year and achieved a consolidated turnover of CHF 464.8 million (previous year: CHF 403.7 million). On its continued growth path, the company trebled its operating result (EBIT) to CHF 28.6 million versus the previous year (previous year: CHF 9.3 million). Compared with the previous year, the net profit increased nearly fourfold to CHF 23.1 million (previous year: CHF 5.8 million). In addition, Ypsomed is planning a capital increase to support the targeted growth.

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) announces changes to the Board of Directors. The founder and Chairman of the Board of Directors of the Ypsomed Group Dr. h.c. Willy Michel will not stand for re-election as Chairman and member of the Board of Directors at the upcoming Annual General Meeting on 29 June 2022. The Board of Directors proposes to the Annual General Meeting 2022 to elect the current member of the Board of Directors, Gilbert Achermann as new Chairman. Simon Michel will be nominated for election as a new member of the Board of Directors.

Press Releases Ypsomed Group

Burgdorf – Ypsomed, Abbott and CamDiab will work to accelerate the development of an automated insulin delivery system for people living with diabetes. The system is being designed to include Abbott’s FreeStyle Libre 3 sensor, CamDiab’s CamAPS FX algorithm, and Ypsomed’s mylife YpsoPump. The partnership demonstrates the companies’ collective desire to drive integrated solutions to help people with diabetes better manage their condition and improve health outcomes.